

Name of Affected Drug	Description of Change	Reason for Change	Effective Date
{16 (SELINEXOR 20 MG ORAL TABLET [XPOVIO]) } PACK [XPOVIO 40 MG TWICE WEEKLY (80 MG TOTAL WEEKLY DOSE) CARTON]	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 8/25/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	10/1/2020
{24 (SELINEXOR 20 MG ORAL TABLET [XPOVIO]) } PACK [XPOVIO 60 MG TWICE WEEKLY (120 MG TOTAL WEEKLY DOSE) CARTON]	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 8/25/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	10/1/2020
BEDAQUILINE 20 MG ORAL TABLET [SIRTURO]	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 8/25/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	10/1/2020
{8 (SELINEXOR 20 MG ORAL TABLET [XPOVIO]) } PACK [XPOVIO 40 MG ONCE WEEKLY CARTON]	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 8/25/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	10/1/2020
12 HR FOSTEMSAVIR 600 MG EXTENDED RELEASE ORAL TABLET [RUKOBIA]	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 8/25/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	10/1/2020
DOLUTEGRAVIR 5 MG TABLET FOR ORAL SUSPENSION [TIVICAY]	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 8/25/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	10/1/2020
FENFLURAMINE 2.2 MG/ML ORAL SOLUTION [FINTEPLA]	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 8/25/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	10/1/2020

Name of Affected Drug	Description of Change	Reason for Change	Effective Date
HELIDAC THERAPY PACK	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 7/27/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	9/1/2020
TERIPARATIDE 620 MCG/2.48 ML	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 7/27/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	9/1/2020
TABRECTA 150 MG TABLET	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 7/27/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	9/1/2020
TABRECTA 200 MG TABLET	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 7/27/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	9/1/2020

Name of Affected Drug	Description of Change	Reason for Change	Effective Date
{14 (CENOBAMATE 100 MG ORAL TABLET [XCOPRI]) / 14 (CENOBAMATE 50 MG ORAL TABLET [XCOPRI]) } PACK [XCOPRI TITRATION PACK - 50 MG (14), 100 MG (14) 28 COUNT]	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 6/24/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	8/1/2020
{14 (CENOBAMATE 12.5 MG ORAL TABLET [XCOPRI]) / 14 (CENOBAMATE 25 MG ORAL TABLET [XCOPRI]) } PACK [XCOPRI TITRATION PACK - 12.5 MG (14), 25 MG (14) 28 COUNT]	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 6/24/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	8/1/2020
{14 (CENOBAMATE 150 MG ORAL TABLET [XCOPRI]) / 14 (CENOBAMATE 200 MG ORAL TABLET [XCOPRI]) } PACK [XCOPRI TITRATION PACK - 150 MG (14), 200 MG (14) 28 COUNT]	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 6/24/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	8/1/2020
{28 (CENOBAMATE 150 MG ORAL TABLET [XCOPRI]) / 28 (CENOBAMATE 200 MG ORAL TABLET) } PACK [XCOPRI 350 MG MAINTENANCE PACK]	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 6/24/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	8/1/2020
{28 (CENOBAMATE 200 MG ORAL TABLET [XCOPRI]) / 28 (CENOBAMATE 50 MG ORAL TABLET [XCOPRI]) } PACK [XCOPRI 250 MG MAINTENANCE PACK]	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 6/24/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	8/1/2020
CENOBAMATE 100 MG ORAL TABLET [XCOPRI]	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 6/24/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	8/1/2020
CENOBAMATE 150 MG ORAL TABLET [XCOPRI]	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 6/24/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	8/1/2020
CENOBAMATE 200 MG ORAL TABLET [XCOPRI]	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 6/24/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	8/1/2020
CENOBAMATE 50 MG ORAL TABLET [XCOPRI]	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 6/24/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	8/1/2020

Name of Affected Drug	Description of Change	Reason for Change	Effective Date
DEFERASIROX 180 MG ORAL TABLET	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 6/24/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	8/1/2020
MICAFLUNGIN SODIUM 100 MG INJECTION	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 6/24/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	8/1/2020
MICAFLUNGIN SODIUM 50 MG INJECTION	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 6/24/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	8/1/2020
NIMODIPINE 6 MG/ML ORAL SOLUTION [NYMALIZE]	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 6/24/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	8/1/2020
NITISINONE 10 MG ORAL CAPSULE	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 6/24/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	8/1/2020
NITISINONE 2 MG ORAL CAPSULE	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 6/24/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	8/1/2020
NITISINONE 5 MG ORAL CAPSULE	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 6/24/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	8/1/2020
RIPRETINIB 50 MG ORAL TABLET [QINLOCK]	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 6/24/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	8/1/2020
SELPERCATINIB 40 MG ORAL CAPSULE [RETEVMO]	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 6/24/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	8/1/2020
SELPERCATINIB 80 MG ORAL CAPSULE [RETEVMO]	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 6/24/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	8/1/2020

Name of Affected Drug	Description of Change	Reason for Change	Effective Date
TUCATINIB 150 MG ORAL TABLET [TUKYSA]	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 6/24/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	8/1/2020
TUCATINIB 50 MG ORAL TABLET [TUKYSA]	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 6/24/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	8/1/2020
ZIPRASIDONE 20 MG INJECTION	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 6/24/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	8/1/2020

Name of Affected Drug	Description of Change	Reason for Change	Effective Date
DIAZOXIDE 50 MG/ML ORAL SUSPENSION	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 5/22/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	7/1/2020
HALOPERIDOL DECANOATE 50 MG/ML INJECTABLE SOLUTION	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 5/22/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	7/1/2020
ELTROMBOPAG 25 MG POWDER FOR ORAL SUSPENSION [PROMACTA]	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 5/22/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	7/1/2020
0.5 UNT DOSES 3 ML INSULIN LISPRO 100 UNT/ML PEN INJECTOR	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 5/22/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	7/1/2020
3 ML INSULIN, REGULAR, HUMAN 100 UNT/ML PEN INJECTOR [NOVOLIN R]	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 5/22/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	7/1/2020
3 ML INSULIN ISOPHANE, HUMAN 100 UNT/ML PEN INJECTOR [NOVOLIN N]	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 5/22/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	7/1/2020
1.5 ML FREMANEZUMAB-VFRM 150 MG/ML AUTO-INJECTOR [AJOVY]	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 5/22/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	7/1/2020
SELUMETINIB 10 MG ORAL CAPSULE [KOSELUGO]	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 5/22/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	7/1/2020
SELUMETINIB 25 MG ORAL CAPSULE [KOSELUGO]	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 5/22/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	7/1/2020

Name of Affected Drug	Description of Change	Reason for Change	Effective Date
PEMIGATINIB 13.5 MG ORAL TABLET [PEMAZYRE]	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 5/22/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	7/1/2020
PEMIGATINIB 4.5 MG ORAL TABLET [PEMAZYRE]	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 5/22/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	7/1/2020
PEMIGATINIB 9 MG ORAL TABLET [PEMAZYRE]	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 5/22/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	7/1/2020

Name of Affected Drug	Description of Change	Reason for Change	Effective Date
LUMATEPERONE 42 MG ORAL CAPSULE [CAPLYTA]	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 4/24/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	6/1/2020
TRIENTINE HYDROCHLORIDE 250 MG ORAL CAPSULE [CLOVIQUE]	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 4/24/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	6/1/2020
3 ML INSULIN ISOPHANE, HUMAN 70 UNT/ML / INSULIN, REGULAR, HUMAN 30 UNT/ML PEN INJECTOR [NOVOLIN]	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 4/24/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	6/1/2020
EVEROLIMUS 0.25 MG ORAL TABLET	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 4/24/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	6/1/2020
EVEROLIMUS 0.5 MG ORAL TABLET	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 4/24/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	6/1/2020
EVEROLIMUS 0.75 MG ORAL TABLET	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 4/24/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	6/1/2020
ATRIAL FIBRILLATION SOTALOL HYDROCHLORIDE 160 MG ORAL TABLET	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 4/24/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	6/1/2020
ATRIAL FIBRILLATION SOTALOL HYDROCHLORIDE 80 MG ORAL TABLET	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 4/24/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	6/1/2020
VALTOCO 10 MG NASAL SPRAY	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 3/25/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	5/1/2020

VALTOCO 5 MG NASAL SPRAY	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 3/25/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	5/1/2020
VALTOCO 20 MG NASAL SPRAY	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 3/25/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	5/1/2020
VALTOCO 15 MG NASAL SPRAY	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 3/25/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	5/1/2020
SECUADO 3.8 MG/24 HR PATCH	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 3/25/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	5/1/2020
SECUADO 5.7 MG/24 HR PATCH	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 3/25/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	5/1/2020
SECUADO 7.6 MG/24 HR PATCH	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 3/25/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	5/1/2020
TIADYLT ER 120 MG CAPSULE	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 3/25/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	5/1/2020
TIADYLT ER 180 MG CAPSULE	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 3/25/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	5/1/2020
TIADYLT ER 240 MG CAPSULE	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 3/25/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	5/1/2020
TIADYLT ER 300 MG CAPSULE	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 3/25/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	5/1/2020
TIADYLT ER 420 MG CAPSULE	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 3/25/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	5/1/2020

BIVIGAM 10% VIAL	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 3/25/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	5/1/2020
ESTROGEL 0.06% GEL	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 3/25/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	5/1/2020
DERMOTIC OIL 0.01% EAR DROPS	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 3/25/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	5/1/2020
DERMA-SMOOTH-FS SCALP OIL	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 3/25/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	5/1/2020
TAZVERIK 200 MG TABLET	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 3/25/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	5/1/2020
AVAPRITINIB 100 MG ORAL TABLET [AYVAKIT]	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 2/24/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	4/1/2020
AVAPRITINIB 200 MG ORAL TABLET [AYVAKIT]	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 2/24/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	4/1/2020
AVAPRITINIB 300 MG ORAL TABLET [AYVAKIT]	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 2/24/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	4/1/2020
120 ACTUAT BUDESONIDE 0.08 MG/ACTUAT / FORMOTEROL FUMARATE 0.0045 MG/ACTUAT METERED DOSE INHALER	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 2/24/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	4/1/2020
120 ACTUAT BUDESONIDE 0.16 MG/ACTUAT / FORMOTEROL FUMARATE 0.0045 MG/ACTUAT METERED DOSE INHALER	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 2/24/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	4/1/2020

BETAMETHASONE 0.5 MG/ML / CALCIPOTRIENE 0.05 MG/ML TOPICAL LOTION	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 2/24/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	4/1/2020
CLOZAPINE 50 MG ORAL TABLET [CLOZARIL]	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 2/24/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	4/1/2020
CLOZAPINE 200 MG ORAL TABLET [CLOZARIL]	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 2/24/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	4/1/2020
0.5 ML DIAZEPAM 5 MG/ML RECTAL GEL	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 2/24/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	4/1/2020
2 ML DIAZEPAM 5 MG/ML RECTAL GEL	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 2/24/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	4/1/2020
4 ML DIAZEPAM 5 MG/ML RECTAL GEL	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 2/24/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	4/1/2020
FLUOROURACIL 10 MG/ML TOPICAL CREAM [FLUOROPLEX]	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 2/24/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	4/1/2020
12 HR HYDROCODONE BITARTRATE 10 MG EXTENDED RELEASE ORAL CAPSULE	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 2/24/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	4/1/2020
12 HR HYDROCODONE BITARTRATE 15 MG EXTENDED RELEASE ORAL CAPSULE	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 2/24/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	4/1/2020
12 HR HYDROCODONE BITARTRATE 20 MG EXTENDED RELEASE ORAL CAPSULE	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 2/24/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	4/1/2020

12 HR HYDROCODONE BITARTRATE 30 MG EXTENDED RELEASE ORAL CAPSULE	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 2/24/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	4/1/2020
12 HR HYDROCODONE BITARTRATE 40 MG EXTENDED RELEASE ORAL CAPSULE	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 2/24/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	4/1/2020
12 HR HYDROCODONE BITARTRATE 50 MG EXTENDED RELEASE ORAL CAPSULE	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 2/24/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	4/1/2020
3 ML INSULIN ASPART, HUMAN 100 UNT/ML CARTRIDGE	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 2/24/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	4/1/2020
3 ML INSULIN ASPART, HUMAN 100 UNT/ML PEN INJECTOR	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 2/24/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	4/1/2020
INSULIN ASPART, HUMAN 100 UNT/ML INJECTABLE SOLUTION	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 2/24/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	4/1/2020
3 ML INSULIN ASPART PROTAMINE, HUMAN 70 UNT/ML / INSULIN ASPART, HUMAN 30 UNT/ML PEN INJECTOR	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 2/24/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	4/1/2020
INSULIN ASPART PROTAMINE, HUMAN 70 UNT/ML / INSULIN ASPART, HUMAN 30 UNT/ML INJECTABLE SUSPENSION	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 2/24/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	4/1/2020

24 HR TOFACITINIB 22 MG EXTENDED RELEASE ORAL TABLET [XELJANZ]	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 2/24/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	4/1/2020
TRAMADOL HYDROCHLORIDE 100 MG ORAL TABLET	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 2/24/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	4/1/2020
TRIAMCINOLONE ACETONIDE 0.0005 MG/MG TOPICAL OINTMENT	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 2/24/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	4/1/2020
EVEROLIMUS 7.5 MG TABLET	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 1/27/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	3/1/2020
BRUKINSA 80 MG CAPSULE	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 1/27/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	3/1/2020
SUCRALFATE 1 GM/10 ML SUSP	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 1/27/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	3/1/2020
ZELNORM 6 MG TABLET	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 1/27/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	3/1/2020
MESALAMINE ER 0.375 GRAM CAP	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 1/27/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	3/1/2020
EVEROLIMUS 5 MG TABLET	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 1/27/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	3/1/2020
ZOLOFT 20 MG/ML ORAL CONC	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 1/27/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	3/1/2020

PENTAMIDINE 300 MG INHAL POWDR	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 1/27/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	3/1/2020
PENTAMIDINE 300 MG VIAL	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 1/27/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	3/1/2020
DOXEPIN HCL 3 MG TABLET	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 1/27/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	3/1/2020
DOXEPIN HCL 6 MG TABLET	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 1/27/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	3/1/2020
EVEROLIMUS 2.5 MG TABLET	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 1/27/2020; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	3/1/2020
GLUCAGON 3 MG NASAL POWDER [BAQSIMI]	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 12/23/2019; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	2/1/2020
MIDAZOLAM 50 MG/ML NASAL SPRAY [NAYZILAM]	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 12/23/2019; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	2/1/2020
SPRINKLE DULOXETINE 20 MG DELAYED RELEASE ORAL CAPSULE [DRIZALMA]	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 12/23/2019; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	2/1/2020
SPRINKLE DULOXETINE 30 MG DELAYED RELEASE ORAL CAPSULE [DRIZALMA]	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 12/23/2019; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	2/1/2020

SPRINKLE DULOXETINE 40 MG DELAYED RELEASE ORAL CAPSULE [DRIZALMA]	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 12/23/2019; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	2/1/2020
SPRINKLE DULOXETINE 60 MG DELAYED RELEASE ORAL CAPSULE [DRIZALMA]	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 12/23/2019; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	2/1/2020
POSACONAZOLE 100 MG DELAYED RELEASE ORAL TABLET	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 12/23/2019; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	2/1/2020
ENTRECTINIB 100 MG ORAL CAPSULE [ROZLYTREK]	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 12/23/2019; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	2/1/2020
ENTRECTINIB 200 MG ORAL CAPSULE [ROZLYTREK]	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 12/23/2019; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	2/1/2020
24 HR DILTIAZEM HYDROCHLORIDE 360 MG EXTENDED RELEASE ORAL CAPSULE [TIADYLT]	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 12/23/2019; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	2/1/2020
DEFERASIROX 360 MG ORAL TABLET	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 12/23/2019; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	2/1/2020
DEFERASIROX 90 MG ORAL TABLET	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 12/23/2019; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	2/1/2020

BARICITINIB 1 MG ORAL TABLET [OLUMIANT]	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 12/23/2019; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	2/1/2020
{56 (ELEXACAFTOR 100 MG / IVACAFTOR 75 MG / TEZACAFTOR 50 MG ORAL TABLET) / 28 (IVACAFTOR 150 MG ORAL TABLET) } PACK [TRIKAFTA (100 MG / 50 MG / 75 MG, 150 MG)]	ADDITION OF DRUG TO FORMULARY	DRUG ADDED TO CY 2020 FORMULARY REFERENCE FILE ON 12/23/2019; ADDITION TO FORMULARY APPROVED BY CLINICAL STAFF	2/1/2020